Dyne Therapeutics (NASDAQ:DYN) 주식

DYNE THERAPEUTICS INC

Dyne Therapeutics

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

QuantumScape QS Stock

Equities

Mid Cap

News

Movers

General

APGE

CRNX

JOBY

KYMR

LNTH

PLUG

SMMT

XPEV

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 퀀텀스케이프(NYSE:QS)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 전고체 배터리 산업화 계약을 체결했다고 발표한 후 64.34% 급등했다.

샤오펑 및 퀀텀스케이프는 지난주 최고 성과를 보여준 11개 중형주 중 일부(7월 7일-7월 13일)

Dyne Therapeutics Inc

DYNASTAR HOLDINGS INC by Dynastar Holdings, Inc.

Dynastar Holdings Inc

Dye & Durham Ltd

DynTek, Inc. Com

iShares U.S. Equity Factor Rotation Active ETF

IDX Dynamic Innovation ETF

DynaResource Inc

Dynatronics Corp

Dynamix Corporation - Class A Ordinary Share

Dynamix Corp

JPMorgan analyst Tessa T Romero remains engaged in discussions about Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) and its DYNE-101 program in DM1, addressing questions about the next step <a href="https://www.benzinga.com/general/biotech">and potential value creation.</a>
Romero&#8217;s note, issued Thursday, highlights Dyne&#8217;s plan to initiate a global Registrational Expansion Cohort in<a href="https://www.benzinga.com/25/01/42923575/why-is-neuromuscular-focused-dyne-therapeutics-stock-trading-lower-on-friday"> the first half of 2026</a>. This move aims to support a submission for U.S. Accelerated Approval based on biomarker and functional data.
The update follows Dyne&#8217;s January announcement of new data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in DM1 patients, reinforcing the company&#8217;s progress toward key clinical milestones.
&#8220;From our perspective, we continue to ponder management&#8217;s decision to proceed with the registrational expansion cohort for DM1 without receiving regulatory blessing on the protocol and relying on prior dialogue from May 2024 to pursue an accelerated approval path in the U.S,&#8221; Romero writes.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44286904/dyne-therapeutics-4-3-billion-peak-sales-potential-analyst-highlights-key-strengths-and-risks" rel="noreferrer noopener">Dyne Therapeutics&#8217; $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks</a>
&#8220;Based on our conversations, it seems like investors generally share our sentiment and are looking for regulatory sign-off to gain more comfort,&#8221; the analyst added.
Romero still has concerns about the existing data and the absence of a recent update or near-term plans for another data release (the last one was on Dec. 6, 2024).
JPMorgan is also considering how these results might impact the expansion cohort, the confirmatory trial, and the broader competitive landscape.
&#8220;Overall, the additional results from the phase 1/2 ACHIEVE trial evaluating DYNE-101 in DM1 raised more questions than answers for us around the emerging clinical profile, and we look for progress that definitively derisks the lead asset and regulatory strategy,&#8221; the analyst writes.
JPMorgan maintains the Neutral rating on DYN, lowering the price target from $18 to $17.
Price Action: DYN stock is down 1.6% at $12.06 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44439352/fda-approves-expanded-use-of-novartis-rare-disease-drug-as-only-treatment-for-rare-type-of-kidney-disease" target="_blank" rel="noreferrer noopener">FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Health Care

Analyst Ratings

JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path

JP Morgan analyst Tessa Romero maintains Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Neutral and lowers the price target from $18 to $17.

Price Target

JP Morgan Maintains Neutral on Dyne Therapeutics, Lowers Price Target to $17

Management

Dyne Therapeutics Appoints Erick J. Lucera As Chief Financial Officer, Effective March 31, 2025

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Buy and maintains $46 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Dyne Therapeutics, Maintains $46 Price Target

Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Buy and maintains $50 price target.

Chardan Capital Maintains Buy on Dyne Therapeutics, Maintains $50 Price Target

- Continued favorable safety profile for DYNE-251 -
- DELIVER Registrational Expansion Cohort is fully enrolled;&nbsp;data from this cohort planned for late 2025 -
- Potential for Biologics License Application submission for U.S. accelerated approval&nbsp;in early 2026 -

Reported Earlier, Dyne Therapeutics Phase 1/2 Trial Update Highlights Sustained Functional Improvement In Duchenne Muscular Dystrophy With Exon 51-Skipping Candidate; Regulatory Submission Targeted For Early 2026

On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>), focused on developing therapies for genetically <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">driven neuromuscular diseases</a>.
The company&#8217;s FORCE platform is designed to overcome limitations in delivery to muscle tissue and the central nervous system (CNS).
Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.
In January, Dyne Therapeutics revealed new data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101, the company&#8217;s lead candidate, in patients with&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/42923575/why-is-neuromuscular-focused-dyne-therapeutics-stock-trading-lower-on-friday" rel="noreferrer noopener">myotonic dystrophy type 1 (DM1)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40692261/muscle-disease-drug-developer-dyne-therapeutics-stock-plunges-after-updated-data-from-duchenne-mu" rel="noreferrer noopener">Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy</a>
Dyne plans to begin a global Registrational Expansion Cohort with the potential to support a submission for U.S. Accelerated Approval based on biomarker and functional data in H1 2026.
Dyne leverages TfR1 Fab-conjugation for drug delivery to muscles. TfR1 is highly expressed in muscle cells. BMO analyst Kostas Biliouris acknowledges potential safety risks associated with TfR1-targeting (anemia, hemorrhage, kidney injury) but notes that the safety in Dyne&#8217;s clinical data appears acceptable.
Analyst Biliouris says Dyne&#8217;s major catalyst and investor debate revolves around the FDA&#8217;s decision on the DM1 regulatory pathway, as this dictates whether Dyne could enter the DM1 market concurrently or behind its competitor Avidity Biosciences, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>)
BMO assumes a traditional approval pathway and sees the DM1 market as large enough to accommodate multiple players, and Dyne could differentiate via potential CNS benefits.
BMO has initiated with an Outperform rating and <a target="_blank" href="https://www.benzinga.com/quote/DYN/analyst-ratings" rel="noreferrer noopener">a price target of $50</a>.
The analyst models around $4.3 billion DYNE-101 peak-risk unadjusted WW sales in 2035.
Price Action: DYN stock is up 2.16% at $12.29 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44283520/viking-holdings-to-see-strong-2025-business-despite-february-slowdown-says-analyst" target="_blank" rel="noreferrer noopener">Viking Holdings&#8217; 2025 Nearly Sold Out, But Goldman Sachs Seeks More Pricing Clarity For 2026</a></li>
</ul>
Photo via Shutterstock.

Initiation

Trading Ideas

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks

BMO Capital analyst Kostas Biliouris initiates coverage on Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Outperform rating and announces Price Target of $50.

BMO Capital Initiates Coverage On Dyne Therapeutics with Outperform Rating, Announces Price Target of $50

Scotiabank analyst Louise Chen initiates coverage on Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Sector Outperform rating and announces Price Target of $50.

Scotiabank Initiates Coverage On Dyne Therapeutics with Sector Outperform Rating, Announces Price Target of $50

Piper Sandler analyst Edward Tenthoff maintains Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Overweight and lowers the price target from $53 to $48.

Piper Sandler Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $48

HC Wainwright &amp; Co. analyst Andrew Fein maintains Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Buy and lowers the price target from $55 to $46.

HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $46

Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) reported quarterly losses of $(0.88) per share which beat the analyst consensus estimate of $(0.99) by 11.11 percent. This is a 19.27 percent increase over losses of $(1.09) per share from the same period last year.

Earnings

Earnings Beats

Dyne Therapeutics Q4 2024 GAAP EPS $(0.88) Beats $(0.99) Estimate

Guggenheim analyst Debjit Chattopadhyay reiterates Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) from Buy to Buy.

Guggenheim Reiterates Buy on Dyne Therapeuticsto Buy

WIIM

Dyne Therapeutics shares are trading higher after the company announced it received FDA Fast Track designation for DYNE-101 to treat myotonic dystrophy type 1.

Dyne Therapeutics Given FDA Fast Track Designation For DYNE-101 To Treat Myotonic Dystrophy Type 1

RBC Capital analyst Luca Issi reiterates Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Outperform and maintains $45 price target.

RBC Capital Reiterates Outperform on Dyne Therapeutics, Maintains $45 Price Target

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Buy and maintains $55 price target.

HC Wainwright & Co. Reiterates Buy on Dyne Therapeutics, Maintains $55 Price Target

<h3>Gainers</h3>
<ul>
<li>Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) shares moved upwards by 49.8% to $6.74 during Friday's pre-market session. The company's market cap stands at $51.7 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock increased by 36.44% to $1.61. The market value of their outstanding shares is at $4.0 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares rose 32.8% to $0.11. The market value of their outstanding shares is at $13.0 million. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock rose 24.06% to $3.3. The market value of their outstanding shares is at $163.5 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares rose 22.83% to $4.25. The market value of their outstanding shares is at $3.6 million. </li>
<li>Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) stock increased by 18.33% to $0.51. The company's market cap stands at $303.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>IGM Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) stock fell 67.8% to $2.0 during Friday's pre-market session. The market value of their outstanding shares is at $118.9 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock declined by 31.8% to $0.92. The company's market cap stands at $17.3 million. </li>
<li>Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) shares decreased by 18.47% to $1.06. The company's market cap stands at $130.9 million. </li>
<li>Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) stock declined by 13.8% to $19.87. The market value of their outstanding shares is at $2.0 billion. </li>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) stock declined by 13.18% to $62.99. The market value of their outstanding shares is at $2.1 billion. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock declined by 12.36% to $1.49. The company's market cap stands at $60.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKYA

CLDI

DHAI

DTIL

IGMS

MRSN

SCNI

SENS

TMDX

ZVSA

12 Health Care Stocks Moving In Friday's Pre-Market Session

Press Releases

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Comments

Dyne Therapeutics

뉴스

파트너 / 기고자

벤징가 글로벌